Log In
BCIQ
Print this Print this
 

Inflectra, Remsima, biosimilar infliximab (CT-P13)

  Manage Alerts
Collapse Summary General Information
Company Celltrion Inc.
DescriptionHumanized mAb against tumor necrosis factor (TNF) alpha
Molecular Target Tumor necrosis factor (TNF) alpha
Mechanism of ActionAntibody; Biosimilar
Therapeutic ModalityBiologic: Antibody

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

$1,700.0M

$1,700.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

09/03/2015

$1,700.0M

$1,700.0M

0

08/14/2014

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today